Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

Open access
Li, Xian-Yang, Moesta, Achim K., Xiao, Christos, Nakamura, Kyohei, Casey, Mika, Zhang, Haiyan, Madore, Jason, Lepletier, Ailin, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Jacoberger-Foissac, Celia, Wong, Clifford, dela Cruz, Tracy, Welch, Megan, Lerner, Alana G., Spatola, Bradley N., Soros, Vanessa B., Corbin, John, Anderson, Ana C., Effern, Maike, Hölzel, Michael, Robson, Simon C., Johnston, Rebecca L., Waddell, Nicola, Smith, Corey, Bald, Tobias, Geetha, Nishamol, Beers, Courtney, Teng, Michele W. L., Smyth, Mark J.·2019·Cancer Discovery

Abstract

We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor models, we contrast the potency and mechanism of anti-CD39 mAbs with other agents targeting the adenosinergic pathway. We demonstrate the critical importance of an eATP–P2X7–ASC–NALP3-inflammasome–IL18 pathway in the antitumor activity mediated by CD39 enzyme blockade, rather than simply reducing adenosine as mechanism of action. Efficacy of anti-CD39 activity was underpinned by CD39 and P2X7 coexpression on intratumor myeloid subsets, an early signature of macrophage depletion, and active IL18 release that facilitated the significant expansion of intratumor effector T cells. More importantly, anti-CD39 facilitated infiltration into T cell–poor tumors and rescued anti–PD-1 resistance. Anti-human CD39 enhanced human T-cell proliferation and Th1 cytokine production and suppressed human B-cell lymphoma in the context of autologous Epstein–Barr virus–specific T-cell transfer. Significance: Overall, these data describe a potent and novel mechanism of action of antibodies that block mouse or human CD39, triggering an eATP–P2X7–inflammasome–IL18 axis that reduces intratumor macrophage number, enhances intratumor T-cell effector function, overcomes anti–PD-1 resistance, and potentially enhances the efficacy of adoptive T-cell transfer. This article is highlighted in the In This Issue feature, p. 1631

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0541

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 68 references

Cited by

See all 264

Metadata

Authors
Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., Jacoberger-Foissac, C., Wong, C., dela Cruz, T., Welch, M., Lerner, A. G., Spatola, B. N., Soros, V. B., Corbin, J., Anderson, A. C., Effern, M., Hölzel, M., Robson, S. C., Johnston, R. L., Waddell, N., Smith, C., Bald, T., Geetha, N., Beers, C., Teng, M. W. L., & Smyth, M. J.
Venue
Cancer Discovery
Published
2019-12-01
Volume
9
Issue
12
Pages
1754-1773
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2986950076
Cited by
264
References
68
FWCI
18.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0541
The paper
Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., Jacoberger-Foissac, C., Wong, C., dela Cruz, T., Welch, M., Lerner, A. G., Spatola, B. N., Soros, V. B., Corbin, J., Anderson, A. C., . . . Smyth, M. J. (2019). Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0541

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.